OncoAssure Announce Results of Clinical Validation of Prognostic Test for Prostate Cancer

OncoAssure Ltd (www.oncoassure.com), an Irish molecular diagnostics company, announced the results of the clinical performance of its OncoAssure Prostate prognostic test on 11th September 2022 at the European Society of Medical Oncology (ESMO) Congress in Paris.

OncoAssure Prostate is a 6-gene expression test for identifying patients with lower risk of recurrence who are either candidates for active surveillance or require reduced monitoring post-treatment. The test determines the risk of aggressive disease post-diagnosis and the risk of biochemical recurrence over a 5-year period post-surgery.

The results of the development and validation studies,  performed on over 600 prostate tumour samples, demonstrate that OncoAssure Prostate can further stratify patients within the typically used clinical risk categories, based on their personal molecular risk profile.

In the external validation study, involving 203 patients from the Swedish Urology Prostate Cancer (UPCA) cohort, excellent performance was demonstrated for both the 6-gene molecular risk score (MRS) and the composite molecular and clinical risk score (MCRS) with area-under-the-curve (AUC) values of 0.75 and 0.83 respectively. These values compare favorably to that of the commonly used clinical risk stratification tools including the European Association of Urology (EAU) risk categories and the UCSF Cancer of the Prostate Risk Assessment (CAPRA) score, with AUC values of 0.69 and 0.76 respectively. OncoAssure Prostate provides improved prognostic stratification and can inform optimal patient management post-diagnosis.

Des O’Leary, CEO, OncoAssure, said, "We had a very successful ESMO meeting this year and are extremely satisfied with the positive feedback to the data we presented. We received significant endorsement and support from the clinical and scientific communities for our plans to bring OncoAssure Prostate to the market.” 

OncoAssure is a medical diagnostics company that identifies, develops, and commercialises clinically important biomarkers to significantly improve cancer management and treatment. We aim to help clinicians provide the right treatment to the right patient at the right time.  https://www.oncoassure.com/